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Summary 
An antibody was detected in the sera from patients with systemic lupus erythematosus (SLE) 
and central nervous system (CNS) involvement that reacted with a 50-kD antigen in the plasma 
membrane of brain synaptic terminals. The 50-kD  antigen was solubilized with Triton X-100 
from preparations enriched with synaptic plasma membranes, and was partially purified by molecular 
sieve filtration column chromatography.  The sera of 19 of 20 CNS-SLE patients showed strong 
to moderate immunoreactivity  with the 50-kD protein in Western blots. Immunoreactivity  with 
the 50-kD  protein was also detected in the cerebrospinal fluid of CNS-SLE patients.  Control 
sera from healthy individuals did not react with the 50-kD protein. Low to background reactivity 
was detected in 35%  of a group of SLE patients without CNS manifestations,  and in 3% of 
patients  displaying other connective tissue diseases. A total of 100 individuals were tested in 
this study. Purified autoantibodies  to the 50-kD protein from CNS-SLE patients were used for 
immunofluorescent labding of neuroblastoma  cells. The immunofluorescent staining  revealed 
a distinct macular distribution pattern on the surface of the cell membrane. Taken together, the 
data suggest that the 50-kD protein may be an important target for autoantibodies, preponderantly 
found in CNS-SLE patients,  and that the antigen may play a role in the pathogenesis of some 
neurological  manifestations in SLE. 
S 
Ystemic lupus erythematosus (SLE) is an autoimmune dis- 
ease characterized by multiple autoantibodies and myriad 
clinical manifestations.  Central nervous system (CNS) 1 in- 
volvement is a major clinical feature of SLE recognized in 
35-75% of the patients. It is most commonly manifested as 
organic brain syndrome, psychosis, and seizures, indicating 
a diffuse and reversible involvement of the CNS (1-3) with 
corresponding anatomical lesions (4, 5). Routine serological 
tests show that serum autoantibodies to nuclear proteins and 
DNA, and serum complement levels, are less reliable indi- 
cators for active neuropsychiatric disorders in SLE than other 
manifestations  of SLE, such as skin eruptions or nephritis 
(6). Therefore, the diagnosis of CNS-SLE is difficult and re- 
mains based on exclusion. 
A useful tool for identification and characterization of mol- 
ecules associated with CNS-SLE are the brain-reactive an- 
1 Abbreviations  used in  this paper:  CNS,  central  nervous  system;  CSF, 
cerebrospinal fluid. 
toantibodies detected in these patients. Serum autoantibodies 
crossreacting with neuronal antigens  have been implicated 
in the pathogenesis and onset of overt neuropsychiatric dis- 
orders in CNS-SLE (3). Correlations  have been found be- 
tween brain crossreactive lymphocytotoxic  autoantibodies in 
patient's  serum or in cerebrospinal fluid (CSF) and neuro- 
psychiatric  disorders, as well as between neuroblastoma binding 
serum autoantibodies  and clinical nervous system dysfunc- 
tion in SLE (7-9). In neuroblastoma  cells, a 97-kD mem- 
brane protein of unknown function is the target antigen for 
autoantibodies from a limited number of CNS-SLE patients 
(10). Furthermore, autoantibody reactivity with neurofila- 
ment (11) and the ribosomal P protein (12) has been associated 
with SLE. The latter showed good correlation with neuro- 
psychiatric involvement in SLE; therefore, synthetic ribosomal 
P peptide can now be used to assay for respective autoanti- 
bodies and hopefully to identify patients with psychosis sec- 
ondary to SLE (13). In the search for a target antigen that 
could be useful as a more general marker for CNS involve- 
ment in SLE and that could also be putatively involved in 
the immunopathogenic mechanisms of this disease, we uti- 
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blotting to screen sera from a large sample of SLE patients 
with and without CNS manifestations. The rationale for using 
a synaptic membrane preparation was based on the assump- 
tion that an autoantibody that has a putative pathogenic role 
in CNS-SLE is most likely to be directed against a functional 
surface molecule with a key location in the neuronal popula- 
tion of the brain. We report here that a neuronal membrane 
antigen of 50 kD in synaptic terminals is a target for autoan- 
tibodies in SLE patients with CNS involvement. 
Materials and Methods 
Study Population.  Sera  were obtained from 100 individuals. Of 
these, 43 were diagnosed with SLE and fulfilled the American Col- 
lege of Rheumatology criteria. All SLE patients were antinuclear 
antibody (ANA) positive and most tested positive for anti-double- 
stranded DNA. Further serological  testing of the SLE patients was 
not performed due to obvious disease symptoms. 20 of the SLE 
patients were diagnosed with CNS disorders in addition to active 
SLE. Of the 20 patients, 5 were male. About half of the female 
patients had no record of pregnancies. Clinical diagnosis of CNS 
activity in these patients was determined independently of  the tests 
performed in this study. CNS manifestations included seizures, psy- 
chosis, severe  protracted headaches, visual blurring, photophobia, 
acute organic brain syndrome, cerebrovascular  accident (infarction 
and  hemorrhage),  and  transverse myelitis. None of the  CNS 
manifestations could be attributed to a coexisting disease other than 
SLE. The 23 SLE patients without CNS involvement  had no known 
current or previous neurological manifestations. All SLE patients 
had no prior transfusion record. The non-SLE patients included 
one patient with rheumatoid vasculitis and acute organic brain syn- 
drome,  six patients with rheumatoid  arthritis,  three with poly- 
myositis, eight with progressive systemic sclerosis, 10 with chronic 
schizophrenia, three with hypertensive cerebrovascular accidents, 
five with idiopathic seizure disorders, and one with paraneoplastic 
cerebdlar  degeneration.  20 individuals were normal.  The well- 
defined ribonucleoprotein La-positive serum as well as the crude 
recombinant La antigen and bacterial control used in this study 
were a generous gift from Dr. K. B. Elkon (Comell University, 
Ithaca, NY). Defined anti-Ro human antisera were a gift from Dr. 
John B. Harley (Oklahoma Medical Research Foundation). Rabbit 
calreticulin  and  rabbit  anti-calreticulin  antibody  were  kindly 
provided by Dr. Richard Fine (Boston University Medical School). 
Antigen Preparation.  Approximately  400 g of  bovine brain cortex 
were used. After removal  of  the meninges the gray matter was sepa- 
rated by suction, and synaptic plasma membranes were prepared 
from the gray matter using the methanol of  Jones and Matus (14). 
All buffers contained 1 #M PMSF and aprotinin (both from Sigma 
Chemical Co., St. Louis, MO) as proteolytic inhibitors. The gray 
matter was diluted 1:1 with 10% sucrose, homogenized in a blender 
(Waring,  New Hartford, CT) and centrifuged  in  a GSA rotor 
at  2,500 rpm  (DuPont Co.,  Wilmington, DE)  for 20 min  at 
4~  The superuatant was centrifuged in an SS-34 rotor at 7,500 
rpm for 20 min at 4~  the resulting pellet diluted in 10 mM Tris 
buffer, pH 7.4, and made to 34% sucrose using a 48% sucrose 
stock solution. This material was overlaid with 28.5% sucrose and 
centrifuged for 2 h at 22,000 rpm in an SW 27 rotor (Beckman 
Instruments, Inc., Fullerton, CA). The interface was collected and 
washed with 10 mM Tris buffer by centrifugation in a Ti 45 rotor 
at 33,000 rpm for 60 min at 4~  The yield was 3.2 mg/g of  tissue. 
Electron microscopical evaluation of the synaptosomal pellet re- 
vealed some large mitochondria, however, the subsequent osmotic 
shock and gradient centrifugation eliminated most of this contam- 
ination. In addition the mitochondrial fraction tested negative for 
the 50-kD antigen. The pellets were treated with 0.5% Triton X-100 
to solubilize the membranes. Extracted proteins were separated on 
a Sephadex G-100 column (1  x  96 cm) using 10 mM Tris buffer, 
pH 7.4, with 0.5% Triton X-100 and 1 mM EDTA. Fractions of 
2 ml were collected and assayed  by SDS-PAGE. Protein-containing 
fractions were assayed  by immunoblot with serum from CNS-SLE 
patients diluted  1:200. 
Electrophoresis and Iramunoblotting.  SDS-PAGE  was performed 
according to the method of Laemmli (15). Gradient gels (5-15%) 
were used and stained with coomassie blue where indicated. Elec- 
trophoretic transfer  of  proteins to nitrocellulose  was performed  using 
a transfer apparatus (Bio-Rad Laboratories, Richmond, CA) ac- 
cording to manufacturer's procedure. Nitrocellulose filters (Bio-Rad 
Laboratories) were fixed in isopropanol and saturated with 0.1% 
BSA and 0.05% Tween-20 in Tris-buffered saline (TBS), pH 7.5. 
Filters were incubated at 4~  overnight with human serum diluted 
1:200 in TBS containing 0.1% BSA and 0.05% Tween-20, or with 
CSF diluted 1:2. Control sera were used at dilutions of 1:100. After 
three washes with TBS containing 0.05% Tween-20, the filters 
were incubated with peroxidase-conjugated goat anti-human an- 
tibody (Boehringer Mannheim Biochemicals, Indianapolis, IN) for 
I h at room temperature diluted with TBS containing 0.1% BSA 
and 0.05%  Tween-20. After three washes with TBS containing 
0.05% Tween-20 and one wash with 20 mM Tris and 0.5 M NaC1, 
pH 7.5 bands were visualized with 4-chloro-l-naphthol  (Bio-Rad 
Laboratories) and 0.015% hydrogen peroxide. 
Serum Fractionation.  Serum from a strongly positive CNS-SLE 
patient was precipitated with ammonium  sulfate at 40% satura- 
tion, washed two times, dissolved, and dialyzed overnight against 
100 mM "Iris buffer, pH 7.8. Ig fractionation was performed by 
fast performance liquid chromatography (Pharmacia Fine Chem- 
icals, Piscataway, NJ). The dialyzed Ig was loaded on a Mono-Q 
ion exchange column (Pharmacia Fine Chemicals) equilibrated in 
the same buffer as above. Fractions were eluted using 15-50% of 
0.5 M NaC1 in 100 mM Tris buffer, pH 7.8, linear gradient, and 
dialyzed against PBS immediately. 
Immunofluorescence.  B104 rat  neuroblastoma  cells (16) were 
grown on coverslips in RPMI supplemented with 5% FCS and 
5% horse serum. Coverslips were coated with poly-D-lysine  and 
fibronectin (Sigma Chemical Co.) for cell adhesion. Confluent B104 
cells were rinsed in PBS and fixed  in 4% paraformaldehyde for 30 
min. Fixed and unfixed cells were washed in PBS/0.1% BSA and 
incubated with FPLC-purified Ig diluted 1:200 in PBS/0.1% BSA 
for 2 h at room temperature or with affinity-purified antiserum 
at XXX. The cells  were washed three times with PBS and incubated 
for 45 min at room temperature with goat anti-human Ig con- 
jugated to fluorescein. After three washes in PBS/0.1% BSA, the 
cells were rinsed once in PBS and mounted in fluoromount  (Lip- 
shaw). Slides were examined under an Axiomat microscope (Carl 
Zeiss) and photographed  on a Kodak TMAX 400 film. 
Absorption of Patients Sera.  Tissues  (5 g) from bovine brain, 
kidney, spleen, heart, and lung were finely diced and then homo- 
genized in a Dounce glass homogenizer (Wheaton Scientific,  Mill- 
ville, NY). Homogenates from each tissue were washed three times 
with 20 ml of PBS containing  1 #M PMSF and aprotinin (both 
from Sigma Chemical Co.) by centrifugation  at 2,000 g at 4~ 
for 20 min.  Each homogenate  pellet was resuspended in equal 
volume of serum for 2 h at 4~  After centrifugation  at 2,000 g 
for 20 min at 4~  the resulting supernatant was used as absorbed 
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sorptions were performed.  For some immunofluorescence experi- 
ments, a partially purified 50-kD protein fraction was conjugated 
to CNBR Sepharose 4B beads. The conjugated  protein  fraction 
was combined with an equal volume of FPLC-purified serum, in- 
cubated as above and centrifuged at 400 g for 5 min. The supema- 
tant was used as controls  for immunofluoresceuce  experiments. 
A.~nity Purification of  Human Antiserum.  Partially  purified prep- 
aration of the 50-kD protein was subjected to SDS-PAGE and dec- 
trophoretic transfer onto nitrocellulose membrane. The membranes 
were fixed, washed, and blocked as described above and incubated 
overnight  at 4~  with the serum from a CNS-SLE patient.  The 
membranes were washed and stored. The first lane of each mem- 
brane was treated with alkaline phosphatase-conjugated anti-human 
antibody. This reaction was visualized with a solution of 100 mM 
Tris, pH 9,  100 mM NaC1, 5 mM MgC1, 0.3 mg/ml nitro  blue 
tetrazolinm,  and 0.15 mg/ml bromo 4-chloro-3-indoyl phosphate 
(Pharmacia Fine Chemicals). This reaction was used to demark the 
50-kD area on the remaining nitrocellulose membrane. The appro- 
priate area on the remaining nitrocellulose membrane was excised 
and  the bound  antibody was eluted by incubation with  a  small 
volume of 0.1 M  glycine buffer, pH 2.3. The eluted antibody was 
neutralized with 0.5 M Tris-HC1 buffer, pH 8.0, and dialyzed against 
PBS.  Purified antibody was  stored in PBS/1%  BSA. 
Results 
The 50-kD neuronal  membrane protein was detected by 
Western blotting experiments using an extract of  bovine brain 
tissue and sera from SLE patients with CNS abnormalities 
(Fig.  1 A,  lane I).  Synaptic plasma membranes  showed an 
enrichment in the 50-kD protein content using the same sera 
in Western blotting experiments (Fig. 1 A, lane 2). The pro- 
tein appears to be integral to the synaptic plasma membrane, 
since it could only be solubilized with detergent.  Chroma- 
tography of a Triton X-100-solubilized synaptic plasma mem- 
brane preparation on a G-100 column yidds fractions enriched 
with  the  50-kD protein  as shown on the Western blot of 
Figure 2.  SDS-PAGE and coomassie 
blue staining of the hydroxyhpatite  chro- 
matography of fractions 20-22  of the 
G-100  column  show  codution  of the 
50-kD protein with another protein of 
65 kD at 75 mM phosphate concentra- 
tion (lane 4). Lane I  has bovine brain- 
coated vesicles used as protein standard; 
lanes 2 and 3 represent fractions eluting 
just before the 50-kD protein. 
the SDS-PAGE of these fractions (Fig. 1 B, lanes I0-12). These 
fractions  were pooled,  and  the detergent  was removed by 
repeated concentration and dilution using Centricone filtra- 
tion  system (Amicon  Corp.,  Danvers,  MA).  After dialysis 
against 5 mM potassium phosphate buffer, the pooled frac- 
tions  were  chromatographed  on  a  small  hydroxylapatite 
column using a 20-200-mM linear potassium phosphate gra- 
dient. The 50-kD protein eluted at 70 mM potassium phos- 
phate concentration. The protein coduted with a 65-kD pro- 
tein (Fig. 2, lane 4), and no other proteins were detected in 
this  fraction by coomassie blue stain. 
Fractions from the G-100 column chromatography enriched 
in 50-kD protein content as well as purified synaptic plasma 
membranes and sera of patients with CNS-SLE, SLE, normal 
individuals,  and patients with unrelated diseases  were used 
in Western blotting experiments to screen for serum binding 
(representative reactivities are shown on Fig. 3, lanes 1-12) 
to establish whether the presence of the autoantibody to the 
50-kD protein is restricted to patients with CNS-SLE. The 
Figure 1.  (A) Immunoblot of brain bovine homogenate (lane 1) and 
synaptosomal membranes (lane 2) using serum from a CNS-SLE patient. 
(B) Immunoblot of fractions from G-100 column chromatography of solu- 
bilized bovine brain synaptic plasma membranes using the serum of the 
same patient as in A. Lanes 1-13 represent the immunoblot of fractions 
10-23 of the G-100 column. The 50-kD molecuh duted in fractions 20-22, 
shown in lanes  10-12. 
Figure 3.  Representative immunoblots from the screen of CNS-SLE, 
SLE patients, patients with unrelated diseases, and normal individuals using 
bovine brain synaptic plasma membranes. Lanes I-5 represent immuno- 
blots with serum from subjects with: CNS-SLE with monospecificity to 
the 50-kD protein (lane I) and CNS-SLE (lane 2-5). Lane 6 shows a CNS- 
SLE patient with very low reactivity. Lanes 7, 8, and 10 show representa- 
tive reactivities of sera from the group of SLE patients without CNS dis- 
orders found reactive with the 50-kD protein. Lane 9 shows a patient with 
rheumatoid arthritis. Lane 11 shows nonreactive serums from patients with 
SLE, and lane 12 is a normal human serum control. 
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20 were patients with CNS-SLE, 23 with SLE without known 
neurological disease, 20 normal individuals, six were patients 
with rheumatoid arthritis, three with polymyositis, one with 
rheumatoid vasculitis,  and the remaining were patients with 
unrelated  diseases  such  as  progressive  systemic  sclerosis, 
schizophrenia, stroke, idiopathic seizure disorders, and para- 
neoplastic cerebellar degeneration. The 20 patients with CNS- 
SLE displayed a variety of CNS manifestations ranging from 
seizures,  psychosis, and severe protracted headaches to acute 
organic brain syndrome, visual blurring, and sensorimotor 
polyneuropathy (Table 1). In addition to the CNS abnormal- 
ities, these patients had active SLE symptoms including skin 
manifestations, nephritis, pleuropericarditis, and polyarthritis. 
At the time of sampling of the sera for reactivity with the 
50-kD protein,  19 patients  had active CNS disease. 
Table  1.  Summary of CNS-SLE Patients Tested Positive for 
Autoantibody Reactivity with the 50-bD Protein 
CNS-SLE 
Patients 
Anti-50-kD 
Age  Sex  reactivity  CNS manifestations 
yr 
25  F  + +  Headache, visual blurting, 
photophobia 
15  F  + +  Organic brain syndrome 
32  F  + +  Seizures, vertigo,  headaches 
24  M  + +  Seizures, nausea, photophobia 
29  F  + +  Transverse myelitis, 
intracerebral hemorrhage 
67  F  + +  Polyneuropathy,  acute organic 
brain  syndrome 
38  M  + +  Psychosis 
31  F  +  Seizures, psychosis 
30  F  +  Psychosis 
39  F  -  h/o* psychosis, depression 
18  F  +  Psychosis 
24  M  + +  Seizures, psychosis 
16  F  + +  Transverse myelitis 
28  F  + +  Transient  ischemic event, 
headaches 
14  F  +  Transient  ischemic event 
19  F  + +  Pseudotumor  cerebri 
30  F  + +  Psychosis 
27  F  +  Cerebrovascular accident 
35  F  + +  Seizures 
24  F  +  Psychosis 
We found strong autoantibody reactivity in all but one 
of the patients with active CNS-SLE (Table 2). This patient 
had a history of CNS-SLE with depression and psychosis, 
but did not have active disease at the time of blood sampling. 
None of the normal individuals displayed reactivity with the 
50-kD molecule. A low level of reactivity was detected in 
35% of the SLE patients without CNS involvement, while 
the remaining SLE patients did not react with the 50-kD 
protein. We could not ascertain any particular clinical or sero- 
logical correlations present in the 35% of the reactive SLE 
patients. The incidence of positivity in patients with unrelated 
diseases was <3%  and involved a patient with rheumatoid 
vasculitis and organic brain syndrome. Moreover, in this case 
the reactivity was very weak. 
Western blots were also performed using CSF samples from 
patients  with  CNS-SLE,  SLE,  or normal individuals  and 
purified synoptic plasma membranes. CSF samples of five CNS- 
SLE patients were assayed and showed reactivity with the 
50-kD protein. A representative reactivity is shown in Fig. 
4, lane 2. Autoantibody reactivity to the 50-kD protein was 
absent in CSF of normal patients.  Two patients with SLE 
were also tested and displayed no reactivity (not shown). 
To determine whether the 50-kD molecule is brain specific, 
we screened several bovine tissue extracts for the presence of 
this protein. The serum from a patient with strong reactivity 
with the 50-kD protein was used in Western blotting with 
homogenates from brain, spleen, lung, skeletal muscle, heart 
muscle, liver, and kidney. As shown in Fig. 5 B, the patient's 
serum reacts strongly with a protein of the same molecular 
mass in liver (lane 7), kidney (lane 6), spleen (lane 2), and 
brain (lane 1). Weak reactivity was present in skeletal muscle 
(lane 4) and lung (lane 3),  and no reactivity was found in 
heart  musde  (lane  5).  To  characterize further  the  tissue 
specificity and molecular homogeneity of the 50-kD protein, 
serum samples from CNS-SLE patients were absorbed with 
various tissue homogenates before Western blotting on syn- 
optic membrane preparations. Preincubation of serum with 
brain homogenate was most efficient in removing the serum 
Table  2.  Presence  or Absence of Anti-50-kD Reactivity by Diagnosis 
Neuronal  50-kD 
Diagnosis  positivity 
CNS-SLE 
SLE without CNS 
Rheumatoid vasculitis with OBS ~ 
Rheumatoid arthritis 
Polymyositis 
Progressive systemic sclerosis 
Chronic schizophrenia 
Hypertensive cerebrovascular accident 
Idiopathic seizure disorders 
Paraneoplastic cerebellar degeneration 
19/20 
8/23 
1/1 
0/6 
0/3 
0/8 
0/10 
0/3 
0/5 
0/1 
Range:  strong positive,  + +; moderately positive,  +; negative,  -. 
" History of.  * Organic brain syndrome. 
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protein can be detected in the CSF of CNS-SLE pa- 
tients by immunoblot. Lane 1 represents the immu- 
nobiot of bovine brain synaptic membrane prepara- 
tion with the serum of a CNS-SLE patient. Lane 
2 represents the immunoblot of synaptic membrane 
fractions with the CSF from the same patient. 
reactivity in Western blots (Fig. 5 A, lane 2). Serum adsorp- 
tion with kidney (Fig 5 A, lane 1), liver, and spleen homo- 
genates diminished serum reactivity with brain but could not 
remove this reactivity completely even after long preincuba- 
tion times and multiple absorptions. 
To  ascertain  that  the  50-kD  antigen described here is 
different from other known 50-kD antigens associated with 
SLE, we studied the crossreactivity  of purified antibodies to 
the 50-kD antigen with the ribonudear protein La(SS-B) and 
calreticulin, a protein of identical amino acid sequence with 
the human Ro(SS-A) antigen. Further, we looked at the cross- 
reactivity of rabbit antisera  to calreticulin and well-defined 
autoantibodies to the Ro and La antigens with our 50-kD 
antigen preparations. As shown in Fig. 6 A, lanes 3-5, human 
anti-Ro antisera did not crossreact with our 50-kD antigen 
preparation, nor did defined anti-La antisera (Fig. 6 C, lanes 
1 and 2). In addition, purified anti-50-kD antiserum did not 
crossreact with calreticulin (Fig. 6 B, lane 3) and anticalretic- 
ulin antisera  showed no reactivity with our 50-kD antigen 
preparation. 
We examined the surface distribution of the 50-kD mole- 
cule using B104 rat neuroblastoma cells and serum from a 
CNS-SLE patient with strong reactivity to this protein. The 
Ig fraction from this serum was precipitated with ammo- 
Figure 5.  (A) Western blot of bovine brain synaptic plasma membrane 
preparation with serum from a CNS-SLE patient with anti-50-kD reac- 
tivity and preabsorbed with kidney (lane 1) and brain (lane 2). Both reac- 
tivities are shown adjacent  to low molecular mass markers.  (B) Western 
blot of bovine tissue homogenates using serum from a CNS-SLE patient 
with high antibody titer to the 50-kD protein. Lane I, brain; lane 2, spleen; 
lane 3, hng; lane 4, skeletal muscle;  lane 5, heart muscle;  lane 6, liver; 
lane 7, kidney. (C) Western blot of bovine brain homogenate using serum 
from a CNS-SLE patient fractionated by FPLC ion ~change chromatog- 
raphy. The peak fraction containing the 50-kD reactivity is shown in lane 
2 adjacent  to low molecular mass markers.  Lane 1 shows  the reactivity 
of the whole serum adjacent  to low molecular mass markers. 
nium sulfate and subsequently fractionated by ion exchange 
chromatography. We obtained an Ig fraction that showed re- 
activity specific for the 50-kD protein in Western blots of 
whole bovine brain homogenates (Fig.  5 C, lane 2) as well 
Figure 6.  (A)  Immunoblot  of 
partially  purified  50-kD  protein 
from bovine brain synaptic plasma 
membranes  using  purified serum 
from two CNS-SLE patients with 
positive reactivity (lanes 1 and 2, 
respectively)  and wen-defined hu- 
man antisera to the Ro antigen from 
three patients with SLE (lanes 3, 4 
and 5, respectively).  (B) Immuno- 
blot of  partially  purified  50-kD  pro- 
tein  from bovine  brain  synaptic 
plasma membranes (lanes I  and 3) 
and  calreticulin  (lanes  2  and  4) 
using rabbit antiserum to calretic- 
ulin (lanes I  and 2) and purified anti-50-kD antiserum from a patient with CNS-SLE.  (C) Immunoblot with a well-defined La antigen-positive serum 
on partially  purified 50-kD protein from bovine brain synaptic plasma membranes (lane I and 2), recombinant La antigen (lane 3), and a control bacterial 
extract (lane 4). 
569  Hanson et al. Figure 7.  Immunoblot of human postmortem fetal 
brain homogenate (lane I) and B104 whole cell ho- 
mogenate (lane 2) using purified serum from a CNS- 
SLE patient. 
as in Western blots of human postmortem fetal brain ho- 
mogenate (Fig. 7, lane I) and B104 whole cell homogenate 
(Fig. 7, lane 2). When prefixed but not permeabilized B104 
cells were labeled with this fraction, a distinct macular sur- 
face fluorescence was observed consistently (Fig.  8, A-D). 
Fluorescent patches were seen on the cell body and dendritic 
projections. Two to three large patches were seen per cell in 
most preparations.  Labeling  of unfixed cells gave the same 
localization pattern. Absorption of the Ig fraction with purified 
50-kD protein before incubation with the B104 cells abol- 
ished the macuhr pattern of surface immunofluorescence  (Fig. 
9 A). The residual immunofluorescence  seen in cells treated 
with absorbed autoantibody is nonspecific as it occurs in cells 
treated with normal human serum as well. Cells labeled with 
serum from SLE patients without CNS disease exhibited (not 
shown) nondescript diffuse surface fluorescence. To examine 
the intracellular distribution of this protein, B104 ceils were 
stained with purified Ig from a CNS-SLE patient after call 
membrane permeabilization with Triton X-100. The observed 
immunofluorescence  was in the perinudear area and confined 
to granular-vesicular  organdies (Fig. 9 B). Cell nucleus and 
nudeoli were not stained.  Immunofluorescent localization 
of the 50-kD antigen was also performed  with affinity-purified 
anti-50-kD autoantibody from a CNS-SLE patient. Affinity- 
purified antibody was obtained by elution from the 50-kD 
band in Western blots as described in Materials and Methods. 
The reactivity of the affinity-purified  antibody in Western 
blot is shown in Fig. 10, lane 3. The immunofluorescent  lo- 
calization  pattern of this antibody (Fig.  11, A  and B) is es- 
sentially  the same as stated above. Absorption of affinity- 
purified anti-50-kD antibody with partially purified 50-kD 
protein preparation removed the macular surface immuno- 
fluorescence  (Fig.  11 C). 
Figure 8.  Immtmofluorescent  hbeling of BIlM neuroblastoma cells with 
purified anti-50-kD autoantibody from a CNS-SLE patient. One to three 
patches  of intense fluorescence per cell are usually observed. 
Discussion 
We have found that an antibody to a 50-kD neuronal cell 
surface antigen appears in patients with active CNS disease 
secondary to SLE. In addition, we showed that purified Ig 
from the sera of these CNS-SLE patients react with the 50-kD 
antigen derived from fetal human brain. This lends support 
to the postulate that the reactive antibody in the sera from 
CNS-SLE patients is an autoantibody by ruling out the pos- 
sibility of a heteroantibody interaction. Further support of 
this postulate is the improbability of alloantibody genera- 
tion in most patients with CNS-SLE in our study, as this 
group of patients did not include transfused subjects and the 
majority of the patients were males or females without prior 
pregnancy record. The strongest indication of autoantibody 
reactivity against the 50-kD antigen, however, is the selec- 
tive patient population in which it occurs. The incidence of 
positive immunoreactivity  in 95% of the CNS-SLE patients 
studied is as high as the one made by Bonfa and Elkon (12) 
for the association  of autoantibodies to the P protein with 
lupus psychosis. The finding that 35% of unselected SLE pa- 
tients showed low levels of serum reactivity with the 50-kD 
antigen could conceivably identify a group of SLE patients 
with subdinical CNS disease. Omdal et al. (17) reported that 
25  of 30  randomly selected  SLE patients (83%),  studied 
retrospectively, showed mild neuropsychiatric manifestations 
such as migraine and protracted headache, and conduded that 
clinical  evaluation often failed to identify such disorders. 
In the course of our work we observed that the reactivity 
of autoantibodies to the 50-kD protein is stronger in patients 
with severe neurological disorders such as seizures. The level 
of autoantibodies to the 50-kD antigen may become an indi- 
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cent  hbdinoo  of  B104 neuroblastoma 
cells  with anti-50-kD  autoantibody 
preabsorbed  with partially  purified 
50-kD protein. (B) Immunolluores- 
cent  hbding of  permeabilized  B104 
neuroblastoma cells with purified 
anti-50-kD autoantibody. 
cator for the severity of the CNS disease since the only CNS- 
SLE patient that showed no reactivity to  the antigen was 
in remission at the time of  blood sampling. Future long-term 
longitudinal studies will address this possibility. 
The 50-kD protein is an autoantigen present on the sur- 
face of neuronal ceils. Although the identity of the antigen 
is unknown at the present, it appears to be distinct from pre- 
viously described intracdlular antigens, induding Ro, Sm- 
RNP, and the ribosomal protein (12, 18). The molecttlar mass 
of 50-kD coincides with that of the 50-kD protein part of 
the La (SS-B) small ribonudeoprotein found to complex with 
RNA  polymerase III  transcripts  (19).  However,  the  im- 
munofluorescent localization pattern of the 50-kD antigen 
described here differs from that of the La antigen insofar that 
the latter is exdusivdy a nudear antigen whereas the former 
shows cell surface membrane localization and it is absent from 
Figure 10.  Immunoreactivity  of  serum 
from  a patient  with CNS-SLE  in a West- 
ern blot of brain homogenate  (hne I). 
The immunoreactivity  of  the same  serum. 
after  aff~ty  purification  is shown  in lane 
3. Lanes  2 and 4 are low molecular  mass 
markers. 
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the nucleus of the tested cell types. Anti-La antibody-posi- 
tive patients have been reported to have a later age of disease 
onset, low frequency of lupus nephritis (20),  and no associa- 
tions of anti-La reactivity with CNS disease (2). Furthermore, 
we have shown that well-defined La positive serum does not 
react with the 50-kD synaptic membrane protein. The anti- 
50-kD antibodies do not crossreact with rabbit calreticulin, 
a  protein of identical amino acid sequence,  as the human 
R.o/SS-A antigen (21), which is often a target for autoanti- 
bodies in SLE patients. Alternatively, well-defined human an- 
tisera to the ILo antigen did not crossreact with the neuronal 
50-kD antigen. Reactivities of rabbit antisera raised against 
whole brain homogenates to surface molecules of similar size 
(53 kD) have been reported in the A2 neuroblastoma cell line 
(22).  Absorption studies show that the 53-kD A2 neuroblas- 
toma antigen is a brain-specific antigen. Although liver, spleen, 
and kidney were inef~cient in absorbing the 50-kD reactivity 
from CNS-SLE sera in the present study, the dear reactivity 
of these sera with the same tissues by Western blots excludes 
the possibility of neuronal specificity for the 50-kD protein. 
The  50-kD  antigen  appears,  therefore, different from the 
53-kD brain antigen identified in A2 neuroblastoma calls. 
The 50-kD antigen is a distinct neuronal membrane pro- 
tein common for brain and neuroblastoma cells. Neuroblas- 
toma cell lines have commonly been used to identify brain- 
reactive antibodies in SLE in attempts to aid diagnosis and 
to explain the pathogenesis in CNS-SLE (23).  However, no 
dear associations have been shown so far. How et al.  (24) 
demonstrated that 43% of CNS-SLE patients show reactivity 
with unidentified target antigens in neuroblastoma cell lines 
compared with 14% of unsdccted SLE patients. A later study 
of Hanly et al. (10) identified the first target antigen in neu- Figure 11.  (A and B) Immunofluorescent  labeling of B104 neuroblas- 
toma cells with affinity-purified  anti-50-kD autoantibody  from a CNS- 
SLE patient. Immunofluorescence  image  is combined  with differential  in- 
terference  microscopy  image  for better  visualization  of  the immunofluores- 
cent localization  pattern. (C) Immunofluorescent  labeling  of  B104 neuro- 
bhstoma cells  with alfinity-purified  anti-50-kD autoantibody  preabsorbed 
with partially purified 50-kD protein. 
roblastoma calls as a 97-kD protein of surface origin that can 
be precipitated by sdect SLE sera. In their study, two of the 
three patients whose sera precipitated the 97-kD antigen had 
overt neuropsychiatric manifestations.  Although their findings 
suggest that the antigen may be associated with CNS-SLE, 
the study population was too small and a clear clinical corre- 
lation was not established. In the course of our studies we 
found that some CNS-SLE sera also reacted with an antigen 
of"o  100 kD in Western blots on synaptic plasma membranes, 
but the reactivity was inconsistent (data not shown). At present 
there is no published evidence that the 97-kD target antigen 
in neuroblastoma cells is also present in normal brain cells, 
therefore, its rdevance to the mechanism of  CNS-SLE remains 
unknown. 
The 50-kD target protein described here could possibly 
be a clinically rdevant antigen for two reasons: (a) the pres- 
ence of  anti-50-kD autoantibody correlates with CNS mani- 
festations in SLE patients;  and (b) the antigen is expressed 
on the membrane of synaptic endings, a neuronal compart- 
ment vital for normal brain function. The presence of this 
antigen in nonneuronal tissues offers the possibility that it 
is a shared antigen and may reflect similar properties and gene 
expression in these tissues.  In addition, the presence of the 
50-kD antigen in kidney, liver, and spleen may be indicative 
of a pattern of sensitization that occurs initially in the non- 
neuronal environment and causes systemic accumulation of 
autoantibodies. As previously proposed, the onset of CNS 
disease may be coupled with brain barrier dysfunction, which 
may lead to the ingress of the systemically accumulated au- 
toantibody into the CSF (23).  Subsequently the binding of 
the autoantibodies to nerve endings could impose impair- 
ment of neuronal function. It has been postulated that im- 
mune response to brain autoantigens can also be initiated in- 
trathecally, and in fact, increased polyclonal B cell activation 
has been observed within the CNS in patients with CNS- 
SLE (25). Based on our .Western blot experiments using CSF, 
we suggest that autoantibodies to the 50-kD antigen may 
gain access to the CNS. The high serum autoantibody titer 
of the CNS-SLE patients tested in this study, however, favors 
the possibility that the initial immune response resides in the 
systemic circulation. Future studies wRl address the presence 
of autoantibodies to the 50-kD antigen in the CSF of CNS- 
SLE patients  and their respective titers. 
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